Clinical Trial Update: Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lanreotide microparticles for palliative treatment in peritoneal carcinomatosis; completed study assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma
• Intestinal Obstruction
• Peritoneal Neoplasms

Drugs mentioned

• Lanreotide microparticles (lanreotide)

Snippet

Sponsor: Ipsen | Conditions: Intestinal Obstruction, Carcinoma | Phase 3 | Status: COMPLETED